Outsourcing

Eric Langer has over 25 years experience in biotechnology and life sciences strategic marketing management, market research, and publishing. He has held senior management and marketing positions at biopharmaceutical supply companies. He has published and authored many books and reports on topics in Biotechnology, Large-scale BioManufacturing, and bioscience commercialization and communication. He teaches at Johns Hopkins University marketing management, biotech marketing, services marketing, and marketing in a regulated environment. In 1989 he co-founded BioPlan Associates, Inc. to provide market analysis, and strategy to biotech and healthcare organizations.

Articles

Outsourcing activity remains strong and unlikely to abate, especially in more traditional areas.

Biopharma Outsourcing Activities Update

Jim Miller is president of PharmSource Information Services, Inc., and publisher of Bio/Pharmaceutical Outsourcing Report.

Changes in company ownership shake up the CMO industry.

Under New Ownership

CMOs may find opportunities in alternative expression services.

Novel Expression Systems Opening CMO Opportunities

The R&D model is in transition and creating new demands on contract services providers.

R&D in Transition

Ongoing changes create new opportunities for CROs and CMOs.

Climate Change in Outsourcing

Data from BioPlan Associates’ 10th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production suggest that the interest in disposable devices has begun to extend to biopharma operations beyond basic single-use bags and connectors.

Disposable Applications in Demand by Biopharma

Practicality of implementation should be a part of vision in the bio/pharmaceutical industry.

The Expense of Vision in Outsourcing

Advances in techniques and single-use systems are revolutionizing vaccine manufacturing.

Bioprocessing Advances in Vaccine Manufacture

The industry may not be ready for India and China as regulatory issues emerge.

What Happened to Outsourcing in Asia?

Approvals of new drugs are on an upward swing, but only a few CMOs are benefiting.

Outsourcing Outlook